[¹⁷⁷Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease.

IF 9.1 1区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Nuclear Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-24 DOI:10.2967/jnumed.123.265577

Lorenzo Mercolli, Clemens Mingels, Giulia Manzini, Paul Cumming, Konstantinos Zeimpekis, Song Xue, Ian Alberts, Dominik Uehlinger, Axel Rominger, Kuangyu Shi, Ali Afshar-Oromieh

{"title":"[177Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease.","authors":"Lorenzo Mercolli, Clemens Mingels, Giulia Manzini, Paul Cumming, Konstantinos Zeimpekis, Song Xue, Ian Alberts, Dominik Uehlinger, Axel Rominger, Kuangyu Shi, Ali Afshar-Oromieh","doi":"10.2967/jnumed.123.265577","DOIUrl":null,"url":null,"abstract":"We report the dosimetric evaluation of prostate-specific membrane antigen-based radioligand therapy (RLT) for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease. Methods: The patient received hemodialysis during each of 6 RLT cycles while staying as an inpatient. We used voxel dosimetry and blood sampling for the dose calculation. Results: The patient responded well to the RLT, as indicated by the prostate-specific antigen level decreasing from 298 to 7.1 ng/mL. The doses per cycle ranged from 0.19 to 0.4 Gy/GBq for the parotid gland, 0.14 to 0.28 Gy/GBq for the submandibular gland, 0.03 to 0.11 Gy/GBq per kidney, and 0.10 to 0.15 Gy/GBq for the red bone marrow. Conclusion: This case suggests that [177Lu]Lu-PSMA-based RLT can be applied successfully and safely to a patient with chronic kidney disease undergoing hemodialysis.","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1570-1573"},"PeriodicalIF":9.1000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2967/jnumed.123.265577","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

We report the dosimetric evaluation of prostate-specific membrane antigen-based radioligand therapy (RLT) for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease. Methods: The patient received hemodialysis during each of 6 RLT cycles while staying as an inpatient. We used voxel dosimetry and blood sampling for the dose calculation. Results: The patient responded well to the RLT, as indicated by the prostate-specific antigen level decreasing from 298 to 7.1 ng/mL. The doses per cycle ranged from 0.19 to 0.4 Gy/GBq for the parotid gland, 0.14 to 0.28 Gy/GBq for the submandibular gland, 0.03 to 0.11 Gy/GBq per kidney, and 0.10 to 0.15 Gy/GBq for the red bone marrow. Conclusion: This case suggests that [¹⁷⁷Lu]Lu-PSMA-based RLT can be applied successfully and safely to a patient with chronic kidney disease undergoing hemodialysis.

查看原文本刊更多论文

[177Lu]Lu-PSMA-617在慢性肾脏病患者中的治疗。

我们报告了一例自乳头显性多囊肾病患者的前列腺特异性膜抗原放射性配体治疗（RLT）对转移性前列腺癌症的剂量评估。方法：患者在住院期间，在6个RLT周期中的每个周期接受血液透析。我们使用体素剂量测定和血液采样进行剂量计算。结果：患者对RLT反应良好，前列腺特异性抗原水平从298降至7.1 ng/mL。每个周期的剂量范围从0.19到0.4 腮腺的Gy/GBq，0.14至0.28 下颌下腺的Gy/GBq，0.03至0.11 Gy/GBq/肾，0.10至0.15 Gy/GBq。结论：该病例表明基于[177Lu]Lu-PSMA的RLT可以成功且安全地应用于正在接受血液透析的慢性肾脏疾病患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nuclear Medicine 医学-核医学

CiteScore

13.00

自引率

8.60%

发文量

340

审稿时长

1 months

期刊介绍： The Journal of Nuclear Medicine (JNM), self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), provides readers worldwide with clinical and basic science investigations, continuing education articles, reviews, employment opportunities, and updates on practice and research. In the 2022 Journal Citation Reports (released in June 2023), JNM ranked sixth in impact among 203 medical journals worldwide in the radiology, nuclear medicine, and medical imaging category.